Low-sodium diet induces atherogenesis regardless of lowering blood pressure in hypertensive hyperlipidemic mice
Carregando...
Citações na Scopus
7
Tipo de produção
article
Data de publicação
2017
Título da Revista
ISSN da Revista
Título do Volume
Editora
PUBLIC LIBRARY SCIENCE
Citação
PLOS ONE, v.12, n.5, article ID e0177086, 22p, 2017
Resumo
This study investigated the influence of sodium restriction and antihypertensive drugs on atherogenesis utilizing hypertensive (H) low-density lipoprotein-receptor knockout mice treated or not with losartan (Los) or hydralazine (Hyd) and fed low-sodium (LS) or normal-sodium (NS) chow. Despite reducing the blood pressure (BP) of H-LS mice, the LS diet caused arterial lipid infiltration due to increased plasma total cholesterol (TC) and triglycerides (TG). Los and Hyd reduced the BP of H-LS mice, and Los effectively prevented arterial injury, likely by reducing plasma TG and nonesterified fatty acids. Aortic lipid infiltration was lower in Los-treated H-LS mice (H-LS+Los) than in normotensive (N)-LS and H-LS mice. Aortic angiotensin II type 1 (AT1) receptor content was greater in H-NS than H-LS mice and in H-LS+Hyd than H-LS+Los mice. Carboxymethyl-lysine (CML) and receptor for advanced glycation end products (RAGE) immunostaining was greater in H-LS than H-NS mice. CML and RAGE levels were lower in LS animals treated with antihypertensive drugs, and Hyd enhanced the AT1 receptor level. Hyd also increased the gene expression of F4/80 but not tumor necrosis factor-a, interleukin (IL)-1 beta, IL-6, IL-10, intercellular adhesion molecule-1 or cluster of differentiation 66. The novelty of the current study is that in a murine model of simultaneous hypertension and hyperlipidemia, the pleiotropic effect of chronic, severe sodium restriction elicited aortic damage even with reduced BP. These negative effects on the arterial wall were reduced by AT1 receptor antagonism, demonstrating the influence of angiotensin II in atherogenesis induced by a severely LS diet.
Palavras-chave
Referências
- Alderman MH, 2004, J AM SOC NEPHROL, V15, pS47, DOI 10.1097/01.ASN.0000093236.74397.F3
- Alderman MH, 2010, JAMA-J AM MED ASSOC, V303, P448, DOI 10.1001/jama.2010.69
- Beaglehole R, 2011, LANCET, V377, P1438, DOI 10.1016/S0140-6736(11)60393-0
- Bouguerne B, 2011, ANTIOXID REDOX SIGN, V14, P2093, DOI 10.1089/ars.2010.3321
- BRENSILVER JM, 1985, KIDNEY INT, V27, P497, DOI 10.1038/ki.1985.38
- Catanozi S, 2003, J LIPID RES, V44, P727, DOI 10.1194/jlr.M200330-JLR200
- Catanozi S, 2001, ATHEROSCLEROSIS, V158, P81, DOI 10.1016/S0021-9150(01)00415-4
- Cheng C, 2006, CIRCULATION, V113, P2744, DOI 10.1161/CIRCULATIONHA.105.590018
- Curfs DMJ, 2004, AM J PATHOL, V164, P101, DOI 10.1016/S0002-9440(10)63101-X
- Daugherty A, 2004, CIRCULATION, V110, P3849, DOI 10.1161/01.CIR.0000150540.54220.C4
- Dikalov SI, 2014, ANTIOXID REDOX SIGN, V20, P281, DOI 10.1089/ars.2012.4918
- Dikalov SI, 2013, ANTIOXID REDOX SIGN, V19, P1085, DOI 10.1089/ars.2012.4604
- Ferreira DN, 2010, J NUTR, V140, P1742, DOI 10.3945/jn.109.117473
- Fu MX, 1996, J BIOL CHEM, V271, P9982
- Galvani S, 2008, FREE RADICAL BIO MED, V45, P1457, DOI 10.1016/j.freeradbiomed.2008.08.026
- Garg R, 2014, HYPERTENSION, V64, P1384, DOI 10.1161/HYPERTENSIONAHA.114.03880
- Garg R, 2011, METABOLISM, V60, P965, DOI 10.1016/j.metabol.2010.09.005
- Giacco F, 2010, CIRC RES, V107, P1058, DOI 10.1161/CIRCRESAHA.110.223545
- Goel Reema, 2008, Arterioscler Thromb Vasc Biol, V28, P1996, DOI 10.1161/ATVBAHA.108.172270
- Graudal NA, 1998, JAMA-J AM MED ASSOC, V279, P1383, DOI 10.1001/jama.279.17.1383
- Graudal NA, 2012, AM J HYPERTENS, V25, P1, DOI 10.1038/ajh.2011.210
- Humalda JK, 2014, CURR OPIN NEPHROL HY, V23, P533, DOI 10.1097/MNH.0000000000000073
- Ivanovski O, 2005, ATHEROSCLEROSIS, V180, P271, DOI 10.1016/j.athersclerosis.2004.12.020
- Johns C, 1996, HYPERTENSION, V28, P1064
- Kalea AZ, 2009, FASEB J, V23, P1766, DOI 10.1096/fj.08-117739
- KATSUTANI N, 1992, INT J IMMUNOPHARMACO, V14, P673, DOI 10.1016/0192-0561(92)90130-D
- Keidar S, 1999, ATHEROSCLEROSIS, V146, P249, DOI 10.1016/S0021-9150(99)00145-8
- Keidar S, 1997, BIOCHEM BIOPH RES CO, V236, P622, DOI 10.1006/bbrc.1997.6844
- Krikken JA, 2012, NUTR METAB CARDIOVAS, V22, P35, DOI 10.1016/j.numecd.2010.03.010
- Lichtman AH, 1999, ARTERIOSCL THROM VAS, V19, P1938
- Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
- Lopez-Diez R, 2013, GENOME BIOL EVOL, V5, P2420, DOI 10.1093/gbe/evt188
- MITCHELL JA, 1990, DRUG SAFETY, V5, P168, DOI 10.2165/00002018-199005030-00002
- Mouedden Mohammed El, 2007, Pharmacol Biochem Behav, V86, P458, DOI 10.1016/j.pbb.2007.01.003
- Nakandakare ER, 2008, ATHEROSCLEROSIS, V200, P410, DOI 10.1016/j.atherosclerosis.2007.12.034
- Nickenig G, 2000, BRIT J PHARMACOL, V131, P795, DOI 10.1038/sj.bjp.0703623
- Nickenig G, 1997, AM J PHYSIOL-HEART C, V272, pH2701
- PAIGEN B, 1987, ATHEROSCLEROSIS, V68, P231, DOI 10.1016/0021-9150(87)90202-4
- Rugale C, 2007, J CARDIOVASC PHARM, V50, P293
- RUPPERT M, 1994, AM J MED SCI, V307, pS87
- Stolarz-Skrzypek K, 2011, JAMA-J AM MED ASSOC, V305, P1777, DOI 10.1001/jama.2011.574
- Tikellis C, 2012, HYPERTENSION, V60, P98, DOI 10.1161/HYPERTENSIONAHA.112.191767
- National Research Council (US), 2011, GUIDE CARE USE LAB A
- Van Assche T, 2011, J VASC RES, V48, P31, DOI 10.1159/000317398
- Weiss D, 2001, CIRCULATION, V103, P448
- Wiesel P, 1997, HYPERTENSION, V29, P1025
- Zhang YH, 2014, J RENIN-ANGIO-ALDO S, V16, P292
Coleções
Artigos e Materiais de Revistas Científicas - FM/MPT
Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/10
Artigos e Materiais de Revistas Científicas - LIM/16
Artigos e Materiais de Revistas Científicas - LIM/17
Carregar mais Artigos e Materiais de Revistas Científicas - FM/MCM
Artigos e Materiais de Revistas Científicas - HC/ICHC
Artigos e Materiais de Revistas Científicas - LIM/10
Artigos e Materiais de Revistas Científicas - LIM/16
Artigos e Materiais de Revistas Científicas - LIM/17